- Home
- ESLA vs CVM Comparison
ESLA vs CVM Comparison
Compare ESLA & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | CVM |
|---|---|---|
| Founded | 2021 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.9M | 53.1M |
| IPO Year | N/A | 1987 |
Fundamental Metrics
Financial Performance| Metric | ESLA | CVM |
|---|---|---|
| Price | $1.53 | $4.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 127.6K | 73.4K |
| Earning Date | 11-12-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.98 |
| 52 Week High | $3.15 | $21.93 |
Technical Indicators
Market Signals| Indicator | ESLA | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 32.74 |
| Support Level | $1.46 | $4.01 |
| Resistance Level | $1.62 | $6.75 |
| Average True Range (ATR) | 0.21 | 0.48 |
| MACD | -0.02 | -0.11 |
| Stochastic Oscillator | 16.67 | 29.19 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.